BioSpace News Archive

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will participate in a fireside chat at the Needham Healthcare Conference on Tuesday, April 14, 2020 at 12:00 p.m. Eastern Time. The conference will be held in a virtual meeting format. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Seattle Ge

Tests designed to detect both active and past infections in less than 15 minutes, using handheld Nanomix eLab Analyzer

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including colorectal, prostate and leukemia, today announced it will be presenting at the 19th Annual Needham Healthcare Conference at 3:30

The COVID-19 pandemic has created shortages of many critical care items such, as hand sanitizer. Out of concern for its own employees, customers and front-line healthcare worker safety, Vortex Companies is producing its own Anti-Bacterial Soap and Hand Sanitizer and will begin shipping it to its own crews this week.

With the consistently rising numbers of COVID-19, many healthcare systems are becoming quickly overwhelmed in their Emergency Departments, Med-Surge Units and ICU Units.

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc

SOPHiA GENETICS, leader in Data-Driven Medicine, announced today that Lara Hashimoto has joined its Executive Team as Chief Business Officer, effective April 1st.

Today Wise Therapeutics (Wise), a newly formed digital therapeutics company, launched its flagship product, Personal Zen, to assist in combating stress and anxiety. Wise is dedicated to making highly accessible, evidence-based interventions for a broad range of behavioral health problems.

Week two data of the Barometer study from 5,000 physicians in 30 countries conducted by Sermo reveals the emergence of treatment patterns.

Revive Therapeutics Ltd. is pleased to announce that the Company has retained Novotech, the largest biotech clinical research organization (“CRO”) specialist in the Asia-Pacific region, to serve as the Company’s CRO to pursue future human clinical studies for Bucillamine in the treatment o